Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.30 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342514 | 0.71 | ALDH1A1 (0.44) | ALDH1A1DYRK1A | |
| SCHEMBL8128088 | 0.71 | — | — | |
| SCHEMBL1128351 | 0.71 | KDM4E (0.44) | DYRK1BALDH1A1 | |
| SCHEMBL3886600 | 0.69 | CYP1A2 (0.38) | CYP1A2HASPINDYRK1BQPCTQPCTL | |
| SCHEMBL7323328 | 0.68 | TLR9 (0.37) | MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL30995419 | 0.67 | NPC1 (0.41) | DYRK1BPIK3CAFTO | |
| SCHEMBL18757838 | 0.65 | SMN1; SMN2 (0.43) | CYP1A2QPCTQPCTLPIK3CAMEN1 | |
| SCHEMBL5809787 | 0.65 | CCNE2 (0.34) | — | |
| SCHEMBL16517402 | 0.63 | DYRK1B (0.39) | CYP1A2HASPINDYRK1BDYRK1A | |
| SCHEMBL13219255 | 0.63 | MAPK1 (0.38) | CYP1A2HASPINDYRK1BQPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566775-B2 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1301523-B1 | N8 - AND C8 -LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | ROCHE DIAGNOSTICS GMBH (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-20060135462-A1 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-7063945-B2 | N8 -and c8 -linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040171820-A1 | N8-and c8-linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | ROCHE MOLECULAR SYSTEMS, INC | 2004-09-02 | — | — | US | disclosed |
| EP-1301523-A1 | N8 - AND C8 -LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | Roche Diagnostics GmbH (DE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2001072764-A1 | N?8- AND C8¿-LINKED PURINE BASES AND STRUCTURALLY RELATED HETEROCYCLES AS UNIVERSAL NUCLEOSIDES USED FOR OLIGONUCLEOTIDE HYBRIDIZATION | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135462-A1 | N8- and C8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization | NUDT1, NT5C3B, NT5C2 | CYP1A2 3450/4885HASPIN 2220/4885DYRK1B 2928/4885 |
| US-20040171820-A1 | N8-and c8-linked purine based and structurally related heterocycles as universal nucleosides used oligonucleotides hybridization | NUDT1, NT5C3B, NT5C2 | CYP1A2 3027/4885HASPIN 2090/4885DYRK1B 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.